超声造影剂在肾细胞癌中的研究进展  

Advance of ultrasound microbubble contrast agents in renal cell carcinoma

作　　者：葛胜东 邰胜[1] GE Shengdong;TAI Sheng(Department of Urology,First Affiliated Hospital of Anhui Medical University,Hefei,230000,China)

机构地区：[1]安徽医科大学第一附属医院泌尿外科,合肥230000

出　　处：《临床泌尿外科杂志》2021年第4期330-334,共5页Journal of Clinical Urology

摘　　要：肾细胞癌是常见的泌尿系统恶性肿瘤。目前肾细胞癌的诊断、治疗主要通过CT检查、外科手术及术后化疗等方法实现。肾细胞癌超声微泡造影剂具有器官或组织靶向性、增强显像和血管穿透性。可以携带药物或基因穿过肿瘤血管外组织并且诱导释放,有效地增强传递同时减少不良反应,促进了肾细胞癌在分子水平治疗的发展。Renal cell carcinoma is a common malignant tumor of the urinary system.At present,the diagnosis and treatment of renal cell carcinoma are mainly achieved by CT examination,surgery,and postoperative chemotherapy.Renal cell carcinoma ultrasound microbubble contrast agent has organ or tissue targeting,enhanced imaging,and strengthened vascular permeability.It can carry drugs or genes through the extravascular tissue of tumors and induce release,effectively enhance delivery and reduce side effects,and promote the development of renal cell carcinoma treatment at the molecular level.

关 键 词：超声 微泡造影剂 肾细胞癌 诊断 治疗 

分 类 号：R737.11[医药卫生—肿瘤]